ArticlePloS one2025
Systematic analysis of the global, regional, and national burden of subarachnoid hemorrhage from 1990 to 2021.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Trends in mortality and disability-adjusted life years (DALYs) attributable to subarachnoid hemorrhage in South Asia (2000-2023).Neurosurgical review · 2026Review
- Subarachnoid hemorrhage: epidemiology, risk factors, pathogenesis, and clinical therapies.Molecular biomedicine · 2026Review
- Psychometric properties of the Chinese version of the Subarachnoid Hemorrhage Outcomes Tool (SAHOT) in elderly SAH patients.BMC geriatrics · 2026Article
- Access to care, treatment pathways, and outcomes of endovascular treatment for aneurysmal subarachnoid hemorrhage in Kazakhstan: a retrospective cohort study.Frontiers in radiology · 2026Article
- Gastrointestinal dysfunction in aneurysmal subarachnoid hemorrhage: prevalence, clinical correlates, and prognostic implications from a 15-year ICU cohort study.Frontiers in neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Subarachnoid hemorrhage (SAH) is characterized by high rates of morbidity, mortality, and disability, which imposes a heavy disease burden on society and families. Incidence, mortality, disability-adjusted life years (DALYs) and their corresponding age-standardized rates (ASRs) and estimated annual percentage changes (EAPCs) of subarachnoid hemorrhage were analyzed by using GBD 2021 data in our study. Data were further stratified by age, sex, and region. Globally, in 2021, there were 697486 (95% UI, 614334795785) new cases of subarachnoid hemorrhage, 352,810 (309015401474) deaths, and 10.64 million (9.39 to 12.12) DALYs. The burden of subarachnoid hemorrhage showed substantial decline from 1990 to 2021. However, the decline in the age-standardized incidence rate was significantly smaller than the declines in the age-standardized mortality rate and age-standardized DALY rate, with the most pronounced downward trend in East Asia but an increase in sub-Saharan Africa, indicating that our prevention strategies require further refinement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.